Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis)

• Main Authors: Luigi Gargiulo (Author), Luciano Ibba (Author), Angela Alfano (Author), Piergiorgio Malagoli (Author), Fabrizio Amoruso (Author), Anna Balato (Author), Francesca Barei (Author), Anna G. Burroni (Author), Stefano Caccavale (Author), Piergiacomo Calzavara-Pinton (Author), Maria Esposito (Author), Maria C. Fargnoli (Author), Silvia M. Ferrucci (Author), Caterina Foti (Author), Giampiero Girolomoni (Author), Massimo Gola (Author), Mario B. Guanti (Author), Carlotta Gurioli (Author), Manfredi Magliulo (Author), Martina Maurelli (Author), Pietro Morrone (Author), Maria L. Musumeci (Author), Maddalena Napolitano (Author), Michela Ortoncelli (Author), Cataldo Patruno (Author), Bianca M. Piraccini (Author), Elena Pezzolo (Author), Simone Ribero (Author), Mariateresa Rossi (Author), Paola Savoia (Author), Claudio Sciarrone (Author), Benedetta Tirone (Author), Marco Vaccino (Author), Federica Veronese (Author), Antonio Costanzo (Author), Alessandra Narcisi (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Aim: Abrocitinib is a JAK-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). We conducted a 16-week multicenter retrospective study to assess the short-term effectiveness and safety of abrocitinib in patients with moderate-to-severe AD.Our retrospective study includ...